BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $132.2, a high estimate of ...
Praxis Precision Medicines (PRAX) stock falls amid concerns over success in its late-stage trial for lead asset ulixacaltamide in essential tremor. Read more here.
Hosted on MSN25d
PRAX stock soars to 52-week high, hits $90.33 amid robust gainsP raxis Precision Medicines Inc. stock has reached a new 52-week high, with shares climbing to $90.33. According to InvestingPro data, the company's market capitalization now stands at $1.7 ...
Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Praxis Precision Medicines ...
Rezort školstva uvažuje o zmene záverečných prác zavedením alternatívy. Študent by si mohol vybrať buď záverečnú prácu, ...
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing ...
Truist lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $175 and keeps a Buy rating on the shares. The firm is removing ...
2 market experts have recently issued ratings for this stock, with a consensus target price of $130.5.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback